G1 Therapeutics (NASDAQ:GTHX)

Approved after receiving breakthrough destination during Covid for small cell lung cancer. The drug COSELA halts the harmful effects of chemo induced myelosuppression. COSELA may very well turn out to be a blockbuster on all the other indication the drug can be use for. Including Breast cancer which has shown remarkable results and bladder and colon cancers. It may become the standard of care for all chemothearpy patients. With a patent extending to 2035 and designed and invented by a very well known respected government scientist. The stock looks very intriguing. Sales where slow to start because there partner was not equipped to sell the drug. Now they have a new sales team of 38 in place with the keys to the top accounts in onocology with 500 years plus experience and big time management including Jack Bailey the new ceo and the former President from Glaksosmithkine at the helm.

The company, G1 Therapeutics (NASDAQ: GTHX) sits in a sweet spot valuation-wise — cancer biotech companies with valuations between $500 million and $1 billion often are the best performers going into an FDA decision.

That valuation is big enough to suggest a good likelihood of an FDA approval, while still being small enough to produce big gains should it occur.

The company’s drug, trilaciclib, is designed to protect bone marrow cells from being ravaged by chemotherapy drugs. It has been tested in patients receiving chemo drugs for lung cancer. The company recently reported significant improvement in overall survival for patients using the drug. And data have been strong enough to prompt G1 to file an FDA application.

Trilaciclib is also in clinical trials for patients with breast and colorectal cancers. Moreover, G1 has two other compounds in four additional cancer trials.

Sounding the alarm as it detects a spike in activity as insiders position themselves ahead of the company’s FDA approval date — set for Feb. 15, 2021.

Insiders are often in the best position to judge the prospects for a new drug before an FDA event, and a spike like this one suggests that sentiment has turned very bullish.

Moreover, this unusual activity hasn’t just been high for a session or two. It has been high all month!